Top Stories
FDA grants accelerated approval to Kresladi (marnetegragene autotemcel) on March 27, first gene therapy for LAD-I, with PRV issuance for Rocket
The FDA granted accelerated approval on March 27, 2026 to Kresladi (marnetegragene autotemcel), Rocket Pharmaceuticals' lentiviral gene therapy for pediatric patients with severe leukocyte adhesion deficiency type I (LAD-I), per the Rocket Pharmaceuticals press release. It is the first gene therapy approved for LAD-I, a rare X-linked primary immunodeficiency caused by biallelic variants in the ITGB2 gene. The accelerated approval was based on surrogate endpoint data; continued approval may be contingent on verification of clinical benefit in a confirmatory trial. Kresladi uses a lentiviral vector to deliver a functional ITGB2 gene encoding the CD18 protein to autologous hematopoietic stem cells. The approval follows a 2023 complete response letter tied to manufacturing issues at a contract facility, which Rocket subsequently remediated, as Pharmaceutical Technology reported. The FDA also issued a rare pediatric disease priority review voucher, which MedCity News noted currently trade at approximately $200 million on the secondary market. Kresladi received Orphan Drug, Rare Pediatric Disease, Regenerative Medicine Advanced Therapy, and Fast Track designations. Pricing has not been disclosed. Rocket's commercial challenge will center on reaching an ultra-small patient population where LAD-I is not universally included in US newborn screening panels, and where HSCT remains the existing standard of care.
FDA approves Biogen's high-dose SPINRAZA regimen for SMA on March 30, with Phase 2/3 DEVOTE data showing significant motor function gains
The FDA approved a new high-dose regimen of SPINRAZA (nusinersen) for spinal muscular atrophy (SMA) on March 30, 2026, per the Biogen press release. The high-dose regimen consists of two 50 mg loading doses administered 14 days apart, followed by 28 mg maintenance injections every four months — a substantial increase over the current 12 mg regimen that has been on the market for over a decade. BioSpace reported the approval was supported by Phase 2/3 DEVOTE data showing treatment-naïve symptomatic infants on high-dose SPINRAZA achieved statistically significant improvements in motor function versus a matched sham group (CHOP-INTEND mean difference: 26.19 points; p<0.0001). High-dose SPINRAZA is also approved in the EU, Switzerland, and Japan. The approval positions Biogen to recapture competitive ground in SMA, where Novartis's gene therapy Zolgensma and Roche's oral risdiplam (Evrysdi) have gained market share. The dosing change may also affect treatment sequencing decisions, particularly for patients already on low-dose SPINRAZA, and reimbursement discussions for a product whose pricing structure was built around the original 12 mg dose.
Pipeline Watch
Rocket's successful remediation of the manufacturing deficiencies that triggered a 2023 complete response letter, followed by accelerated approval of Kresladi in March 2026, provides a case study in CDMO oversight and regulatory re-engagement for lentiviral vector programs, per MedCity News. The lentiviral manufacturing infrastructure built for Kresladi has multi-program utility — Rocket's pipeline includes gene therapies for Fanconi anemia and pyruvate kinase deficiency. The rare pediatric disease PRV issued alongside the approval, valued at approximately $200 million on the secondary market (per Pharmaceutical Technology), gives Rocket optionality to fund commercialization or pipeline progression.
The March 30, 2026 FDA approval of high-dose SPINRAZA (50 mg loading / 28 mg maintenance) strengthens Biogen's competitive position in SMA against Novartis's one-time gene therapy Zolgensma and Roche's oral risdiplam (Evrysdi), per the Biogen press release. The DEVOTE Phase 2/3 data supporting the approval showed clinically meaningful motor function gains, potentially making a case for new patients to initiate on the higher dose and for existing patients to switch. Reimbursement discussions will be watched closely — Biogen's pricing structure was built around the original 12 mg dose and payer contracts may require renegotiation. The approval also extends SPINRAZA's commercial life cycle in a market where SMA gene therapy adoption continues to grow, particularly in presymptomatic populations identified through newborn screening.
A Drug Channels Institute guest post by PANTHERx Rare CEO Bansi Nagji argues that rare disease pharmacy is not a subset of specialty pharmacy but requires an entirely different operating model built around precision, speed, and hyper-personalized care, per Drug Channels. With over 10,000 rare diseases collectively affecting approximately 30 million Americans, the volume and nature of per-patient interactions in rare pharmacy — including titration management, safety lab coordination, REMS compliance, and caregiver support — are fundamentally different from the generalist call center model of traditional specialty pharmacy. The analysis is directly relevant to the Kresladi and high-dose SPINRAZA commercial launches in this digest: both require specialized distribution and patient support infrastructure that general specialty pharmacies are not designed to provide.
Competitive Landscape
Kresladi joins a set of approved lentiviral gene therapies addressing rare hematopoietic and immune conditions. Each program operates in a distinct indication with limited patient overlap, but shares common commercial pressures: ultra-small populations, payer unfamiliarity, and one-time pricing models that require outcomes-based contracting infrastructure.
| Company | Product | Indication | Approval Status | Approx. US Patients |
|---|---|---|---|---|
| Rocket Pharma | Kresladi | LAD-I | Accelerated Approval 2026 | Under 1,000 |
| Orchard Therapeutics | Lenmeldy | MLD | FDA Approved 2024 | Under 500/yr birth cohort |
| bluebird bio | Zynteglo | Beta-thalassemia | FDA Approved 2022 | ~1,500 eligible US |
| bluebird bio | Skysona | CALD | FDA Approved 2022 | ~40/yr US |
High-dose SPINRAZA approval gives Biogen an updated competitive offering against Zolgensma (one-time gene therapy) and Evrysdi (oral small molecule). Clinicians and payers now face a three-way decision matrix: one-time gene therapy with highest upfront cost, chronic oral dosing with convenience but uncertain long-term data, or enhanced intrathecal ASO with 10+ years of safety history and a new higher-efficacy regimen.
| Company | Product | Modality | Dosing |
|---|---|---|---|
| Biogen | SPINRAZA (nusinersen) high dose | ASO (intrathecal) | 50 mg load / 28 mg q4mo |
| Novartis | Zolgensma (onasemnogene) | Gene therapy (AAV9) | One-time IV |
| Roche | Evrysdi (risdiplam) | Small molecule (oral) | Daily oral |
The Drug Channels analysis underscores that rare disease launches — including gene therapies like Kresladi and dose-modified products like high-dose SPINRAZA — require pharmacy partners capable of cold chain precision logistics, complex titration management, and REMS coordination that traditional specialty pharmacy operations cannot adequately provide. As more gene therapies reach market, the rare pharmacy infrastructure gap may become a bottleneck for commercial ramp.
Forward Looking
- Rocket must disclose Kresladi pricing and outline its payer contracting approach, including whether outcomes-based installment models will be offered for this ultra-small LAD-I population. The decision to sell or retain the ~$200M priority review voucher will signal near-term capital allocation priorities across its Fanconi anemia and pyruvate kinase deficiency pipeline.
- Confirmatory trial enrollment and data timelines for Kresladi (accelerated approval) represent the next regulatory risk event; patient identification constraints from limited newborn screening inclusion for LAD-I could complicate the path to full approval.
- Biogen's reimbursement strategy for high-dose SPINRAZA will be watched closely: pricing relative to the original 12 mg regimen, switching protocols for existing patients, and competitive contracting against Zolgensma and Evrysdi will shape commercial uptake.
- Rare disease specialty pharmacy infrastructure capacity should be monitored as a potential bottleneck for multiple simultaneous gene therapy launches entering commercialization in 2026.